{"resourceType":"ValueSet","id":"2.16.840.1.113762.1.4.1116.608","meta":{"versionId":"5","lastUpdated":"2020-04-29T01:00:18.000-04:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.608","version":"20200429","name":"Bone modifying agents","status":"active","date":"2020-04-29T01:00:18-04:00","publisher":"American Society of Clinical Oncology Steward","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","concept":[{"code":"1046399","display":"Xgeva"},{"code":"105443","display":"Pamidronate Disodium"},{"code":"11473","display":"pamidronate"},{"code":"1546014","display":"zoledronic acid anhydrous"},{"code":"1546406","display":"pamidronic acid"},{"code":"285143","display":"Zometa"},{"code":"705872","display":"Reclast"},{"code":"77655","display":"zoledronic acid"},{"code":"993449","display":"denosumab"},{"code":"993453","display":"Prolia"}]}]}}